New research on pulmonary hypertension ahead of 'Heart Walk' - WTNH.com

New research on pulmonary hypertension ahead of 'Heart Walk' - WTNH.com

New research on pulmonary hypertension ahead of 'Heart Walk' - WTNH.com

Posted: 29 Apr 2019 08:39 AM PDT

(WTNH) - New research is underway in Connecticut for pulmonary hypertension; a devastating disease that lacks a definitive cure.

Dr. Indy Singh is part of a new team with Yale New Haven Hospital called "Cure Pulmonary Hypertension and Right Heart Failure"  which aims to raise awareness and find new treatments through research. The team is currently the top findraising team from Yale. 

The Greater New Haven Heart Walk through the American Heart Association will take place on Saturday, May 4th at Savin Rock Park in West Haven. Registration begins at 9:00am, and the walk steps off at 10:00am. Click here to sign up.

Pulmonary Hypertension and Diabetes: Is There a Link? - Pulmonology Advisor

Posted: 08 Apr 2019 12:00 AM PDT

For patients with type 1 and type 2 diabetes, the lung is often overlooked as a target organ, but there are many respiratory function abnormalities associated with diabetes, according to commentary published in Diabetes Metabolism Research and Review.

Currently, the lung is not considered a potential target organ for diabetes. However, increasing evidence has linked diabetes with respiratory abnormalities including lung volumes, pulmonary diffusing capacity, control of ventilation, bronchomotor tone, and neuroadrenergic bronchial innervation. New evidence has also pointed toward a link between diabetes and pulmonary hypertension (PH).

The researchers noted that patients with diabetes often have decreased lung volumes. Studies have shown that patients with diabetes have a 1.6-fold higher risk for restrictive lung function impairment compared with those who do not have diabetes. Lung function impairment erodes the pulmonary reserve and can lead to repeated respiratory infections, chronic hypoxia, and volume overload.

Other studies have shown that PH is more common among those with diabetes compared with those without. Additionally, patients with diabetes and chronic obstructive pulmonary disease have significantly higher mean pulmonary arterial pressure compared with patients who have chronic obstructive pulmonary disease alone.

Patients with diabetes have related abnormalities that the researchers believe can contribute to PH. Patients with diabetes have significantly thicker epithelial and capillary basal laminas of the alveoli as well as thicker basal laminas in renal tubules and muscle capillaries. Autonomic neuropathy may worsen the inflammatory status of the lung. Additionally, hyperglycemia among patients with diabetes upregulates profibrotic mediators.

Related Articles

"By the moment, there is matter to conclude that fighting [metabolic syndrome] and diabetes would not only prevent major and well recognized complications such as visual loss or renal failure, but also might improve the lung function reserve and smooth the increase in pulmonary artery pressure, whichever is its primary cause," the researchers wrote.

Reference

Fuso L, Pitocco D, Incalzi RA. Diabetic lung, an underrated complication from restrictive functional pattern to pulmonary hypertension [published online March 25, 2019]. Diabetes Metab Res Rev. doi: 10.1002/dmrr.3159

Topics:

General Pulmonology Pulmonary Hypertension

Comments

Post a Comment

Popular posts from this blog

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor

Image
Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Posted: 11 Jul 2019 12:00 AM PDT For patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction, inhaled epoprostenol through high-flow nasal cannula increases oxygenation, according to a study published in Pharmaceutics . The researchers of this retrospective study assessed the effect of inhaled epoprostenol using a high-flow nasal cannula on oxygenation and future mechanical ventilation in patients with hypoxemia comorbid with pulmonary hypertension or right heart dysfunction in an intensive care unit setting. A chart review was completed on adult patients who were admitted into the respiratory care department of the Rush University Medical Center for severe hypoxemia between July 2015 and April 2018 and treated with inha...
Read more

Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News

Image
Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Growing Doubt, Uncertainty Over PDE5i Use in Left Heart Disease - Medscape AnMed Health gains national recognition through the Pulmonary Hypertension Association - WSPA.com Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Posted: 12 Jun 2019 05:00 AM PDT The U.S. Food and Drug Administration (FDA) has approved Novitium Pharma 's generic sildenafil for oral suspension at a dose of 10 mg/mL for the treatment of pulmonary arterial hypertension (PAH). This product, which had been designated a competitive generic therapy by the FDA, is the first approved generic equivalent to Pfizer 's Revatio , a vasodilator agent that induces blood ves...
Read more

Analysis: Large pharma companies do little new drug innovation - STAT

Image
Analysis: Large pharma companies do little new drug innovation - STAT Analysis: Large pharma companies do little new drug innovation - STAT Gene Therapy Takes Center Stage at 2019 NORD Summit - Pulmonary Hypertension News People Living With Type 2 Diabetes Want Information and Empathy From Their Doctors More Than New Medications - PRNewswire Analysis: Large pharma companies do little new drug innovation - STAT Posted: 10 Dec 2019 01:51 AM PST L arge pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug development and the discovery of new medicines, and thus lead to a decline in drug innovation. If that argument is credible, there should be evidence to show that the large pharmaceutical companies are responsible for discovering innovative new drugs. To test that claim, we examined the...
Read more